BRISTOL-MYERS SQUIBB COMPANY

NYSE: BMY (Bristol-Myers Squibb Company)

Kemas kini terakhir: 3 hari lalu, 7:33AM

54.50

0.28 (0.52%)

  • 1H 0.52%
  • 5H -2.54%
  • 1B -0.26%
  • 6B 12.53%
  • Tahun Ke Tarikh 1.95%
  • 1T -10.07%
  • 5T -15.93%
Penutupan Terdahulu 54.22
Buka 54.10
Jumlah Dagangan 15,691,996
Purata Dagangan (3B) 15,492,024
Modal Pasaran 110,948,540,416
Harga / Pendapatan (P/E TTM) 18.35
Harga / Pendapatan (P/E Ke hadapan) 9.13
Harga / Jualan (P/S) 2.34
Harga / Buku (P/B) 6.06
Julat 52 Minggu
42.52 (-21%) — 63.33 (16%)
Tarikh Pendapatan 5 Feb 2026
Hasil Dividen (DY TTM) 1.14%
Margin Keuntungan 11.38%
Margin Operasi (TTM) 31.57%
EPS Cair (TTM) 2.68
Pertumbuhan Hasil Suku Tahunan (YOY) -5.60%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -95.90%
Jumlah Hutang/Ekuiti (D/E MRQ) 293.85%
Nisbah Semasa (MRQ) 1.28
Aliran Tunai Operasi (OCF TTM) 14.31 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 13.93 B
Pulangan Atas Aset (ROA TTM) 7.24%
Pulangan Atas Ekuiti (ROE TTM) 31.99%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Bercampur
Drug Manufacturers - General (Global) Menaik Bercampur
Stok Bristol-Myers Squibb Company Menaik Menurun

AISkor Stockmoo

-0.1
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -1.0
Purata Bergerak Teknikal -3.5
Osilator Teknikal 2.5
Purata -0.13

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
BMY 111 B 1.14% 18.35 6.06
JNJ 530 B 0.56% 19.96 6.64
ABBV 394 B 1.47% 169.09 50.46
MRK 273 B 0.74% 14.44 5.24
PFE 146 B 1.68% 14.91 1.60
GSK 102 B 1.62% 14.06 4.55

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Value
% Dimiliki oleh Orang Dalam 0.07%
% Dimiliki oleh Institusi 82.11%
Julat 52 Minggu
42.52 (-21%) — 63.33 (16%)
Julat Harga Sasaran
37.00 (-32%) — 65.00 (19%)
Tinggi 65.00 (UBS, 19.27%) Beli
Median 60.00 (10.09%)
Rendah 37.00 (Morgan Stanley, -32.11%) Jual
Purata 56.67 (3.98%)
Jumlah 4 Beli, 4 Pegang, 1 Jual
Harga Purata @ Panggilan 53.75
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Leerink Partners 13 Jan 2026 60.00 (10.09%) Beli 55.92
Scotiabank 09 Jan 2026 60.00 (10.09%) Pegang 55.86
04 Dec 2025 53.00 (-2.75%) Pegang 51.95
Citigroup 07 Jan 2026 53.00 (-2.75%) Pegang 56.72
17 Nov 2025 45.00 (-17.43%) Pegang 46.81
UBS 07 Jan 2026 65.00 (19.27%) Beli 56.72
B of A Securities 15 Dec 2025 61.00 (11.93%) Beli 54.29
Guggenheim 12 Dec 2025 62.00 (13.76%) Beli 52.41
Morgan Stanley 12 Dec 2025 37.00 (-32.11%) Jual 52.41
Wells Fargo 10 Dec 2025 55.00 (0.92%) Pegang 51.21
Goldman Sachs 02 Dec 2025 57.00 (4.59%) Pegang 48.25
Papar semua

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
20 Jan 2026 Pengumuman Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
20 Jan 2026 CNBC Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry
12 Jan 2026 Pengumuman Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
02 Jan 2026 Pengumuman Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference
19 Dec 2025 CNBC Nine of the largest pharma companies ink deals with Trump to lower drug prices
19 Dec 2025 Pengumuman Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
18 Dec 2025 Pengumuman Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026
11 Dec 2025 Pengumuman U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
10 Dec 2025 Pengumuman Bristol Myers Squibb Announces Dividend Increase
08 Dec 2025 Pengumuman Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
04 Dec 2025 Pengumuman Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
03 Dec 2025 Pengumuman Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb
03 Dec 2025 Pengumuman Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
01 Dec 2025 Pengumuman Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
26 Nov 2025 Pengumuman Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference
24 Nov 2025 Pengumuman Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
24 Nov 2025 Pengumuman Bristol Myers Squibb to Host Hematology-Focused Investor Event
18 Nov 2025 Pengumuman Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
17 Nov 2025 Pengumuman Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
14 Nov 2025 Pengumuman Update on Phase 3 Librexia ACS Trial
12 Nov 2025 Pengumuman Sarah Cannon Research Institute and Bristol Myers Squibb Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research
05 Nov 2025 Pengumuman Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes
03 Nov 2025 Pengumuman Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025
03 Nov 2025 Pengumuman Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes
30 Oct 2025 Pengumuman Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
27 Oct 2025 Pengumuman Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus
25 Oct 2025 Pengumuman Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
Papar semua
Hasil Dividen (DY TTM) 1.14%
Purata Hasil Dividen 5T 3.20%
Nisbah Pembayaran 91.04%
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
03 Jan 2025 11 Dec 2024 03 Feb 2025 0.62 Tunai
04 Oct 2024 10 Sep 2024 01 Nov 2024 0.6 Tunai
05 Jul 2024 18 Jun 2024 01 Aug 2024 0.6 Tunai
04 Apr 2024 01 Mar 2024 01 May 2024 0.6 Tunai
04 Jan 2024 06 Dec 2023 01 Feb 2024 0.6 Tunai
05 Oct 2023 20 Sep 2023 01 Nov 2023 0.57 Tunai
06 Jul 2023 14 Jun 2023 01 Aug 2023 0.57 Tunai
06 Apr 2023 03 Mar 2023 01 May 2023 0.57 Tunai
05 Jan 2023 08 Dec 2022 01 Feb 2023 0.57 Tunai
06 Oct 2022 14 Sep 2022 01 Nov 2022 0.54 Tunai
30 Jun 2022 15 Jun 2022 01 Aug 2022 0.54 Tunai
31 Mar 2022 01 Mar 2022 02 May 2022 0.54 Tunai
06 Jan 2022 13 Dec 2021 01 Feb 2022 0.54 Tunai
30 Sep 2021 09 Sep 2021 01 Nov 2021 0.49 Tunai
01 Jul 2021 17 Jun 2021 02 Aug 2021 0.49 Tunai
31 Mar 2021 01 Mar 2021 03 May 2021 0.49 Tunai
31 Dec 2020 10 Dec 2020 01 Feb 2021 0.49 Tunai
01 Oct 2020 10 Sep 2020 02 Nov 2020 0.45 Tunai
02 Jul 2020 11 Jun 2020 03 Aug 2020 0.45 Tunai
02 Apr 2020 02 Mar 2020 01 May 2020 0.45 Tunai
02 Jan 2020 06 Dec 2019 03 Feb 2020 0.45 Tunai
03 Oct 2019 12 Sep 2019 01 Nov 2019 0.41 Tunai
03 Jul 2019 14 Jun 2019 01 Aug 2019 0.41 Tunai
04 Apr 2019 08 Mar 2019 01 May 2019 0.41 Tunai
03 Jan 2019 07 Dec 2018 01 Feb 2019 0.41 Tunai
04 Oct 2018 13 Sep 2018 01 Nov 2018 0.4 Tunai
05 Jul 2018 15 Jun 2018 01 Aug 2018 0.4 Tunai
05 Apr 2018 01 Mar 2018 01 May 2018 0.4 Tunai
04 Jan 2018 07 Dec 2017 01 Feb 2018 0.4 Tunai
05 Oct 2017 13 Sep 2017 01 Nov 2017 0.39 Tunai
05 Jul 2017 13 Jun 2017 01 Aug 2017 0.39 Tunai
05 Apr 2017 02 Mar 2017 01 May 2017 0.39 Tunai
04 Jan 2017 08 Dec 2016 01 Feb 2017 0.39 Tunai
05 Oct 2016 03 Aug 2016 01 Nov 2016 0.38 Tunai
29 Jun 2016 07 Jun 2016 01 Aug 2016 0.38 Tunai
30 Mar 2016 03 Mar 2016 02 May 2016 0.38 Tunai
30 Dec 2015 08 Dec 2015 01 Feb 2016 0.38 Tunai
30 Sep 2015 17 Sep 2015 02 Nov 2015 0.37 Tunai
01 Jul 2015 16 Jun 2015 03 Aug 2015 0.37 Tunai
01 Apr 2015 02 Mar 2015 01 May 2015 0.37 Tunai
30 Dec 2014 09 Dec 2014 02 Feb 2015 0.37 Tunai
01 Oct 2014 16 Sep 2014 03 Nov 2014 0.36 Tunai
01 Jul 2014 17 Jun 2014 01 Aug 2014 0.36 Tunai
02 Apr 2014 03 Mar 2014 01 May 2014 0.36 Tunai
31 Dec 2013 19 Dec 2013 03 Feb 2014 0.36 Tunai
02 Oct 2013 17 Sep 2013 01 Nov 2013 0.35 Tunai
02 Jul 2013 19 Jun 2013 01 Aug 2013 0.35 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 0.620 1 1.15
2024 2.40 4 4.24
2023 2.28 4 4.44
2022 2.16 4 3.00
2021 1.96 4 3.14
2020 1.80 4 2.90
2019 1.64 4 2.56
2018 1.60 4 3.08
2017 1.56 4 2.55
2016 1.52 4 2.60
2015 1.48 4 2.15
2014 1.44 4 2.44
2013 0.700 2 1.32
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda